Oragenics Inc (NYSEAMERICAN:OGEN) closed Wednesday’s trading session at $0.90 which is lower than the price of the stock when the company announced that it received more validation for OG716.
Oragenics announced on January 28 that OG716, its lantibiotics compound program was published in the Antimicrobial Agents and Chemotherapy peer review journal. The biopharma revealed that its preclinical study did not demonstrate any side effects or toxicities in hamster models when OG716’s maximum feasible dose was administered. Also, the doses did not affect internal motility.
Researchers observed dose-dependent survival in the animals that had C. difficile and there was no recurrence in the tested upper dose. The results of the study also indicated that the OG716 lantibiotic compound remained in the intestinal tract and was not absorbed into the bloodstream.
“The publication of this study offers additional validation for the safety and tolerability of our lantibiotic program, while simultaneously confirming the potential for our lead candidate for the treatment of CDAD,” pointed out Oragenics CEO Alan Joslyn.
OG716 belongs to a class of Lantibiotics that are peptide antibacterial compounds naturally produced by various types of Gram-positive bacteria. The lantibiotic manufactured by Oragenics are part of the company’s novel antibiotics which it is developing to address various different conditions.
Targeting antibiotic-resistant infections through new and innovative treatments
Joslyn noted in his statement that there is a growing need for new tactics of combatting infections that are resistant to antibiotics. He also added that its lantibiotics compound program’s ongoing development offers the potential for treatment to antibiotic-resistant infections. The company looks forward to providing more updates about OG716 in the future including updates about its availability.
Oragenics produces the OG716 molecule through its lantibiotic discovery and characterization platform. The molecule has already demonstrated positive results including its efficacy results in its nonclinical testing as a treatment for Clostridium difficile infection.
Lantibiotics have been getting a lot of praise and recognition for their action mechanism that allows them to overcome infections that are resistant to antibiotics. Such treatments are important especially now that drug-resistant infections are on the rise. Oragenics wants to lead the market as far as such treatments are concerned.